arrow
M

Marco Ventimiglia

italian ministry of health
H指数:20
被引数:1,075

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Comparative effectiveness and safety of tofacitinib and filgotinib in patients with ulcerative colitis: A propensity score-weighted cohort study

托法替尼与菲戈替尼在溃疡性结肠炎患者中的比较疗效与安全性:一项倾向性评分加权队列研究

2025-08-260
PRE
EUS-Guided Gallbladder Drainage Using a Lumen-Apposing Metal Stent for Acute Cholecystitis: Results of a Nationwide Study with Long-Term Follow-Up

EUS引导下使用管腔贴壁金属支架进行胆囊引流治疗急性胆囊炎: 一项长期随访的全国性研究结果

2024-02-135
OAAI
Ustekinumab is a promising option for the treatment of postoperative recurrence of Crohn's disease
2023-05-068
PRE
SPOSAB ABP 501: A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501

SPOSAB ABP 501: 阿达木单抗生物仿制药ABP 501治疗炎症性肠病患者的西西里前瞻性观察研究

2021-07-0319
PREAI
SPOSAB ABP 501-A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501
2021-05-270
PRE
A propensity score weighted comparison of Vedolizumab, Adalimumab, and Golimumab in patients with ulcerative colitis

维多珠单抗、阿达木单抗和戈利木单抗在溃疡性结肠炎患者中的倾向评分加权比较

2020-12-0120
PREAI
Effectiveness and safety of vedolizumab in biologically naive patients: A real-world multi-centre study

维多珠单抗在生物幼稚患者中的有效性和安全性: 一项真实世界的多中心研究

2020-11-0130
OAAI
Effectiveness of Ustekinumab on Crohn's Disease Associated Spondyloarthropathy: Real-World Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)
2020-10-0911
PREAI